Clinical Trials Using Lanreotide Acetate
Clinical trials are research studies that involve people. The clinical trials on this list are studying Lanreotide Acetate. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Octreotide Acetate before or after Lanreotide Acetate in Comparing Injection Site Pain in Patients with Locally Advanced or Metastatic, Nonfunctional, Well Differentiated Neuroendocrine Tumors
This randomized pilot phase IV trial studies octreotide acetate before or after lanreotide acetate in comparing injection site pain in patients with nonfunctional well differentiated neuroendocrine tumors that have spread from where they started to nearby tissue, lymph nodes, or other places in the body. Antihormone therapy, such as octreotide acetate and lanreotide acetate, may fight neuroendocrine tumors by blocking the use of hormones by the tumor cells.
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Pembrolizumab and Lanreotide Acetate in Treating Patients with Gastroenteropancreatic Neuroendocrine Tumors That Are Recurrent, Metastatic, or Cannot Be Removed by Surgery
This phase Ib / II trial studies how well pembrolizumab and lanreotide acetate work in treating patients with gastroenteropancreatic neuroendocrine tumors that have come back, have spread to other places in the body, or cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Lanreotide acetate may prevent signals that help cancer cells survive and grow. Giving pembrolizumab and lanreotide may work better in treating patients with gastroenteropancreatic neuroendocrine tumors.
Location: Duke University Medical Center, Durham, North Carolina
Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
An observational time and motion study in a clinical oncology setting is utilized in order to measure and compare product attributes and overall product efficiency between lanreotide and octreotide LAR.
Location: The University of Arizona Medical Center-University Campus, Tucson, Arizona